IDH-specific vaccine for high-grade gliomas

The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer ... Author: VJOncology Added: 06/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts